FGEN (FibroGen) מחיר לרווח עתידי
Low revenue predictability due to failures of key drugs creates risks for FibroGen, Inc. (FGEN), as illustrated by the company's forward P/E ratio on a precise GURU.Markets chart, where the latest parameter is 0.00. Patents for fibrosis therapy provide a stable cash flow, while revenue currently relies on Chinese royalties and the search for new market niches.
פילוחי נתונים אנליטיים מרוכזים עבור FibroGen Corporation (FGEN)
Forward P/E determines the stock price relative to expected net income, allowing for an assessment of the premium paid for future business growth. By analyzing the 12-month forward P/E of FibroGen, Inc. (FGEN), an investor can compare market expectations with the company's actual cash deficit, where restructuring and cost reductions become critical factors for achieving stated profitability targets.
